Table S1. Quality of included trials by adjusted Jadad scale

Study ID / Clinical trial code / Sequence
generation / Allocation
concealment / Blinding of
participants / Dropout
addressed / ITT
Apovian CM, 2010[23] / NCT00375492 / Adequate / Adequate / Adequate, DB / Adequate / Y
Buse JB, 2011[24] / NCT00765817 / Adequate / Adequate / Adequate, DB / Adequate / Y
DURATION-3, Diamant M, 2012[25] / NCT00641056 / Adequate / Adequate / OpenLabel / Adequate / Y
Davies M, 2013[26] / NCT01003184 / Adequate / Adequate / OpenLabel / Adequate / Y
Davies MJ, 2009[27] / NCT00360334 / Adequate / Unclear / OpenLabel / Adequate / Y
DeFronzo RA, 2010[28] / NCT00135330 / Adequate / Unclear / OpenLabel / Adequate / Y
Derosa G, 2013[29] / NR / Adequate / Adequate / Adequate, DB / Adequate / Y
Forst T, 2012[30] / NCT01208012 / Adequate / Unclear / OpenLabel / Adequate / N
Harder H, 2004[31] / NR / Adequate / Unclear / Adequate, DB / Adequate / Y
Kadowaki T, 2011[32] / NCT00577824 / Adequate / Unclear / Adequate, DB / Adequate / Y
Li CJ, 2012[33] / NR / Adequate / Adequate / Adequate, DB / Adequate / N
Liutkus J, 2010[34] / NCT00603239 / Adequate / Adequate / Adequate, DB / Adequate / Y
Pratley R, 2011[35] / NCT00700817 / Adequate / Adequate / OpenLabel / Adequate / N
T-emerge-1, Raz I, 2012[36] / NCT00744926 / Adequate / Adequate / Adequate, DB / Adequate / Y
T-emerge-3, Henry RR, 2012[37] / NCT00744367 / Adequate / Adequate / Adequate, DB / Adequate / Y
T-emerge-6, Pratley RE, 2013[38] / NCT00909597 / Adequate / Adequate / Adequate, DB / Adequate / Y
T-emerge-7, Hollander P, 2013[39] / NCT00823992 / Adequate / Adequate / Adequate, DB / Adequate / Y

Note: DB: double blinding; TB: triple blinding; ITT, intention-to-treat analysis; Y: yes; N: no; DURATION: Diabetes Therapy Utilization: researching changes in HbA1c, weight, and other factors through intervention with exenatide once weekly; T-emerge 1:A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.T-emerge 3: A Study of Taspoglutide Versus Placebo for the Treatment of Patients with Type2 Diabetes Mellitus Inadequately Controlled with Metformin plus Pioglitazone.T-emerge 6: A Study of Taspoglutide Versus Pioglitazone in Patients with Type 2 Diabetes. T-emerge-7: A Study of Taspoglutide Versus Placebo for the treatment of Obese patients with Type 2 Diabetes Mellitus inadequately Controlled with Metformin Monotherapy.